Sugi Predict

Sugi Predict / Compounds / SCHEMBL29401577

SCHEMBL29401577

SCHEMBL29401577

CN(C(=O)OCC1c2ccccc2-c2ccccc21)[C@@H](CCCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.50
▸ FOLH1 Q04609 2/20 0.46
▸ TPSAB1 Q15661 2/20 0.44
▸ TPSD1 Q9BZJ3 2/20 0.44
▸ TPSG1 Q9NRR2 2/20 0.44
▸ TLR2 O60603 1/20 0.43
▸ TLR1 Q15399 1/20 0.43
▸ MDM2 Q00987 1/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ MALT1 Q9UDY8 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ACE P12821 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25354991 1.00 KMT2A (0.50) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL25354987 1.00 KMT2A (0.50) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL31688635 0.99 KMT2A (0.52) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL30685999 0.97 KMT2A (0.48) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL30074816 0.97 KMT2A (0.48) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL31714189 0.93 KMT2A (0.45) KMT2AFOLH1TLR2TLR1MDM2
SCHEMBL31714214 0.90 KMT2A (0.43) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL25355565 0.89 KMT2A (0.44) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL25355567 0.89 KMT2A (0.44) KMT2AFOLH1TPSAB1TPSD1TPSG1
SCHEMBL31688560 0.88 KMT2A (0.43) KMT2AFOLH1TPSAB1TPSD1TPSG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2026-01-22 — — US disclosed
EP-4605409-A2 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2025-08-27 — — EP disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 — — US disclosed
WO-2025133085-A1 SELECTIVE NPY5R AGONISTS WITH HIGH CHEMICAL AND METABOLIC STABILITY PEPHEXIA THERAPEUTICS APS (DK) 2025-06-26 — — WO disclosed
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2025-05-22 — — US disclosed
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-12 — — US disclosed
US-20240391960-A1 EXTRACELLULAR CYCLOPHILIN INHIBITOR AND USE THEREOF PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) 2024-11-28 — — US disclosed
WO-2024200838-A1 NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA NOSOPHARM (FR) 2024-10-03 — — WO disclosed
CN-118638187-A Novel cyclosporine derivative and application thereof 深圳湾实验室 2024-09-13 — — CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
CN-118354783-A Extracellular cyclophilin inhibitor and application thereof 北京大学深圳研究生院 2024-07-16 — — CN disclosed
US-20240218021-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-07-04 — — US disclosed
WO-2024086814-A2 CYCLIN INHIBITORS CIRCLE PHARMA, INC. (US) 2024-04-25 — — WO disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 — — CN disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 — — WO disclosed
WO-2023050037-A1 EXTRACELLULAR CYCLOPHILIN INHIBITOR AND USE THEREOF 北京大学深圳研究生院 2023-04-06 — — WO disclosed
EP-4089103-A1 CLPCP PROTEASE-BINDING CYCLIC HEPTAPEPTIDES Universität Duisburg-Essen (DE) 2022-11-16 — — EP disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 — — US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KMT2A 2735/4885FOLH1 2259/4885TPSAB1 3710/4885
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KMT2A 1052/4885FOLH1 1945/4885TPSAB1 2246/4885
US-20240218021-A1 CYCLIN INHIBITORS CCNI, CCNC, CDK2 KMT2A 1479/4885FOLH1 3691/4885TPSAB1 3392/4885
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KMT2A 2325/4885FOLH1 2194/4885TPSAB1 3040/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KMT2A 2293/4885FOLH1 2229/4885TPSAB1 3162/4885
US-20240391960-A1 EXTRACELLULAR CYCLOPHILIN INHIBITOR AND USE THEREOF FKBP14, PPIH, FKBP2 KMT2A 4835/4885FOLH1 88/4885TPSAB1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.